Q32 Bio (QTTB) Short term Debt (2023 - 2026)
Q32 Bio's (QTTB) quarterly Short term Debt came in at $6.2 million in Q1 2026, up 33.83% year-on-year from $4.7 million in Q1 2025, and little changed quarter-over-quarter from $6.2 million in Q4 2025.
Q32 Bio (QTTB) Short term Debt (2023 - 2026) Analysis & Trends
Q32 Bio's Short term Debt history runs 4 years deep, the most recent figure standing at $6.2 million for Q1 2026.
- On a quarterly basis, Short term Debt rose 33.83% year-over-year to $6.2 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 33.83% increase from a year earlier, with the FY2025 full-year figure at $6.2 million, up 101.32% from the prior year.
- Short term Debt was little changed at $6.2 million in Q1 2026 per QTTB's latest filing, from $6.2 million in the prior quarter.
- Across five years, Short term Debt topped out at $6.2 million in Q1 2026 and bottomed at $878000.0 in Q4 2023.
- The 4-year median for Short term Debt is $4.7 million (2025), against an average of $4.2 million.
- Across the five-year window, Short term Debt jumped 306.52% in 2025 and jumped 33.83% in 2026, its largest moves.
- Year by year, Short term Debt stood at $878000.0 in 2023, then jumped by 252.73% to $3.1 million in 2024, then jumped by 101.32% to $6.2 million in 2025, then advanced by 0.06% to $6.2 million in 2026.
- Per Business Quant, the three latest QTTB Short term Debt figures stand at $6.2 million (Q1 2026), $6.2 million (Q4 2025), and $6.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Q32 Bio | 215.66 Mn | 164.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.24 Mn |
| Dec 31, 2025 | 6.24 Mn |
| Sep 30, 2025 | 6.23 Mn |
| Jun 30, 2025 | 6.23 Mn |
| Mar 31, 2025 | 4.66 Mn |
| Dec 31, 2024 | 3.10 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Mar 31, 2024 | 3.09 Mn |
| Dec 31, 2023 | 878,000.00 |